Completed PHASE4 INTERVENTIONAL 1-arm NCT03848507

Impact of Hyperoncotic Albumin to Support Blood Loss Replacement (HYPALB)

Impact of Hyperoncotic Albumin to Support Blood Loss Replacement on Plasma Volume Expansion in Cystectomy Patients.

Sponsor: Insel Gruppe AG, University Hospital Bern

Conditions Blood Loss, Surgical Fluid Retention

Interventions albumin 20%

Updated 7 times since 2019 Last updated: Feb 18, 2020 Started: Mar 18, 2019 Primary completion: Feb 12, 2020 Completion: Feb 18, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03848507, this PHASE4 trial focuses on Blood Loss, Surgical and Fluid Retention and remains completed. Sponsored by Insel Gruppe AG, University Hospital Bern, it has been updated 7 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jul 2023 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2023 [monthly]

Completed PHASE4
Mar 2020 — Jan 2021 [monthly]

Completed PHASE4

Status: Recruiting → Completed

▶ Show 2 earlier versions

Apr 2019 — Mar 2020 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
Mar 2019 — Apr 2019 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Insel Gruppe AG, University Hospital Bern

Data source: Insel Gruppe AG, University Hospital Bern

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bern, Switzerland